NasdaqGS:EWTX
NasdaqGS:EWTXPharmaceuticals

Will Edgewise Therapeutics’ (EWTX) Rising Losses Reshape Its Long-Term Investment Strategy?

Edgewise Therapeutics, Inc. reported its second quarter and six-month earnings for the period ended June 30, 2025, disclosing a net loss of US$36.12 million for the quarter and US$76.91 million for the half-year, both increases from the same periods last year. Although the company's per-share loss for the quarter remained flat at US$0.34, overall losses grew year-over-year reflecting rising expenses or investment activity. Given the rise in net loss while per-share loss stayed unchanged,...
NasdaqCM:LMB
NasdaqCM:LMBConstruction

Will Raised Revenue Guidance and Margin Focus Change Limbach Holdings' (LMB) Long-Term Earnings Narrative?

Earlier this month, Limbach Holdings, Inc. raised its 2025 full-year revenue guidance to a range of US$650 million–US$680 million and reported second-quarter sales of US$142.24 million, up from US$122.24 million a year prior, alongside a higher net income of US$7.76 million. This combination of improved financial outlook and year-over-year profit growth signals operational momentum as the company focuses on higher-margin recurring service contracts. We’ll examine how the updated revenue...